How I treat diffuse large B-cell lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36634531/
Diffuse large B-cell lymphoma (DLBCL) is usually treated with chemoimmunotherapy in curative intention at initial diagnosis. Novel agents have improved the prognosis of high-risk patients in the front-line and relapsed...
Conclusions: Several novel drugs have improved first-line and second-line treatment of DLBCL in clinical practice. De-escalation of low-risk patients reduces acute and late side-effects. New treatment concepts such as CAR-T cells and bispecific antibodies will further improve the outcome of high-risk patients.
Extreme body mass index and survival in newly diagnosed multiple myeloma patients - Blood Cancer Journal
Source : https://www.nature.com/articles/s41408-022-00782-7
Correspondence Open Access Published: Urvi A. Shah orcid.org/0000-0001-8419-1091 1,2 , David J. Lee 5,6 , Sabrin Tahri 6,7 , Even H. Rustad 9,10 , Sham Mailankody orcid.org/0000-0002-2815-9561 1,2 , Alexander...
Conclusions: This comprehensive examination of BMI and survival in newly diagnosed MM patients suggests that underweight and severe obesity are associated with worse survival. Future studies of weight trajectories and body composition may help clarify these observations. Additionally, clinical research to understand if patients with extreme BMI...
Chimeric antigen receptor T-cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36627265/
Multiple myeloma (MM) is a hematologic malignancy defined by the clonal proliferation of transformed plasma cells. Despite tremendous advances in the treatment paradigm of MM, a cure remains elusive for...
Conclusions: In this comprehensive review, the authors describe the development of CAR T-cell therapies in myeloma, the outcomes of notable clinical trials, the toxicities and limitations of CAR T-cell therapies, and the strategies to overcome therapeutic challenges of CAR T cells in the hope of achieving a cure for multiple myeloma.
Budget Impact Analysis of Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US - Clinical Drug Investigation
Source : https://link.springer.com/article/10.1007/s40261-022-01215-w
Background Gene therapy is known to be unaffordable to those who need it the most; however, evidence on the financial impact is limited. Objective This study aimed to estimate the...
Conclusions: This study suggests that the high cost of the gene therapy idecabtagene vicleucel is justifiable due to the low number of rrMM patients.
phase II clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma
Brief Report | Nicola Giesen, Manik Chatterjee, Christof Scheid, Alexandra M Poos, Britta Besemer, Kaya Miah, Axel Benner, Nicole Becker, Thomas Moehler, Ivana Metzler, Cyrus Khandanpour, Andrea Seidel-Glaetzer, Karolin Trautmann-Grill,...
Conclusions: This is the first prospective clinical trial to demonstrate that combined BRAF/MEK inhibition is highly effective in patients with BRAFV600E mutated RRMM and represents a successful targeted precision medicine approach in this disease.